Save time and get answers to complex questions with AI chat
When will latisse patent expire?Can wine consumption affect lipitor's cholesterol lowering ability?Zemdri plazomicin nce gain exclusivity 2028 patent 2031?Pramlintide fda approval date?Zemdri plazomicin gain exclusivity 2028 patent 2031?
See the DrugPatentWatch profile for ruxolitinib
I don’t have real-time access to FDA’s current approval data. As of the last widely available information, there hasn’t been a well-publicized FDA approval of Apotex’s generic ruxolitinib in the U.S. Jakafi (ruxolitinib) remains the branded product, and generics are usually delayed by patent protection and exclusivity. To verify the exact status right now, you can check: - FDA Drugs@FDA database for ruxolitinib and look for ANDA status and applicant (Apotex). - FDA Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations) for any entry listing Apotex as the ANDA sponsor and its approval status. - Apotex’s own website or press releases. - Your pharmacist, who can confirm current availability in your area. If you’d like, I can guide you through reading the FDA entries or help interpret any document you have. And if you want me to look up the latest status, tell me and I can search for the most recent official updates.
Other Questions About Ruxolitinib :